Benzinga · Aug 14, 2026
HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Atrium Therapeutics (NASDAQ:RNA) with a Buy and maintains $25 price target.
RN
NASDAQ · RNA
Avidity Biosciences, Inc.
Healthcare · Biotechnology
$12.84
Down-$0.12 (-0.93%)
Updated Aug 19, 2026, 7:16 AM
SID Score
5.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 9.4B
- P/E ratio
- -20.36
- Dividend yield
- 0.00%
- 52-week range
- $11.13 – $73.06
- Volume
- 107.92K
- Avg. volume
- 5.22M
Price performance
RNA price history
1M range · 21 trading sessions · Daily adjusted prices
RNA closed at $12.84 after 21 trading sessions, up 4.48% for the selected period.
- Last close
- $12.84
- Period change
- +4.48%
- Period low
- $11.18
- Period high
- $12.96
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $12.91 | $12.96 | $12.72 | $12.84 | 107.92K |
| Aug 17, 2026 | $12.78 | $13.345 | $12.78 | $12.96 | 212.55K |
| Aug 14, 2026 | $12.21 | $12.97 | $12.08 | $12.84 | 176.08K |
| Aug 13, 2026 | $12.21 | $12.46 | $12.0301 | $12.33 | 127.14K |
| Aug 12, 2026 | $12.27 | $12.35 | $12.06 | $12.17 | 84.17K |
| Aug 11, 2026 | $12.25 | $12.44 | $12.195 | $12.27 | 84.25K |
| Aug 10, 2026 | $12.25 | $12.44 | $12.20 | $12.24 | 108.98K |
| Aug 7, 2026 | $12.15 | $12.485 | $12.145 | $12.34 | 103.29K |
| Aug 6, 2026 | $11.96 | $12.31 | $11.875 | $12.11 | 193.1K |
| Aug 5, 2026 | $11.53 | $11.99 | $11.46 | $11.74 | 171.86K |
| Aug 4, 2026 | $11.40 | $11.74 | $11.35 | $11.54 | 137.01K |
| Aug 3, 2026 | $11.45 | $11.525 | $11.30 | $11.33 | 91.51K |
| Jul 31, 2026 | $11.44 | $11.54 | $11.20 | $11.35 | 116.29K |
| Jul 30, 2026 | $11.19 | $11.5475 | $11.19 | $11.46 | 91.84K |
| Jul 29, 2026 | $11.46 | $11.46 | $11.13 | $11.18 | 119.41K |
| Jul 28, 2026 | $11.59 | $11.625 | $11.355 | $11.49 | 91.97K |
| Jul 27, 2026 | $11.61 | $11.80 | $11.46 | $11.57 | 82.82K |
| Jul 24, 2026 | $11.98 | $11.98 | $11.48 | $11.49 | 120.94K |
| Jul 23, 2026 | $12.00 | $12.14 | $11.78 | $11.91 | 101.29K |
| Jul 22, 2026 | $12.28 | $12.35 | $12.09 | $12.17 | 99.94K |
| Jul 21, 2026 | $11.73 | $12.35 | $11.61 | $12.29 | 181.99K |
Latest RNA news
The latest Smart Investors Daily articles mentioning RNA.
Stock researchCompany · Overview
RNA research
Overview
Company profile and research snapshot.
Company profile
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $74.44
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 18, 2026 | Cantor Fitzgerald | Overweight | — |
| May 15, 2026 | Leerink Partners | Outperform | — |
| Mar 11, 2026 | Wells Fargo | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 13, 2026
Atrium Therapeutics Q2 EPS $(1.18) Misses $(1.01) Estimate, Sales $3.004M Beat $2.000M Estimate
Atrium Therapeutics (NASDAQ:RNA) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.01) by 16.83 percent. This is a 2.48 percent increase over losses of $(1.21) per share
Benzinga · Aug 13, 2026
Benzinga's Volume Movers
Benzinga · Aug 6, 2026
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
